
David A Stephens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2304179/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Semiparametric Bayesian inference for optimal dynamic treatment regimes via dynamic marginal structural models. Biostatistics, 2023, 24, 708-727.	1.5	3
2	Adaptive treatment strategies for chronic conditions: shared-parameter G-estimation with an application to rheumatoid arthritis. Biostatistics, 2022, 23, 430-448.	1.5	2
3	A Bayesian Approach to Modeling Multivariate Multilevel Insurance Claims in the Presence of Unsettled Claims. Bayesian Analysis, 2022, 17, .	3.0	4
4	Predicting missing links in global host–parasite networks. Journal of Animal Ecology, 2022, 91, 715-726.	2.8	4
5	Causal inference: Critical developments, past and future. Canadian Journal of Statistics, 2022, 50, 1299-1320.	0.9	2
6	Bayesian latent multiâ€state modeling for nonequidistant longitudinal electronic health records. Biometrics, 2021, 77, 78-90.	1.4	10
7	Bayesian inference for continuous-time hidden Markov models with an unknown number of states. Statistics and Computing, 2021, 31, 57.	1.5	5
8	The Role of Phylogenetics in Unravelling Patterns of HIV Transmission towards Epidemic Control: The Quebec Experience (2002–2020). Viruses, 2021, 13, 1643.	3.3	9
9	Commentary on "The Statistician in Medicine―by Professor Sir Austin Bradford Hill. Statistics in Medicine, 2021, 40, 37-41.	1.6	0
10	Parametric models for combined failure time data from an incident cohort study and a prevalent cohort study with follow-up. International Journal of Biostatistics, 2021, 17, 283-293.	0.7	3
11	Parametric modelling of prevalent cohort data with uncertainty in the measurement of the initial onset date. Lifetime Data Analysis, 2020, 26, 389-401.	0.9	2
12	Estimating sparse networks with hubs. Journal of Multivariate Analysis, 2020, 179, 104655.	1.0	3
13	Interview with Professor Adrian FM Smith. International Statistical Review, 2020, 88, 265-279.	1.9	0
14	A note on the applicability of the standard nonparametric maximum likelihood estimator for combined incident and prevalent cohort data. Stat, 2020, 9, e280.	0.4	3
15	A hierarchical Bayesian model for predicting ecological interactions using scaled evolutionary relationships. Annals of Applied Statistics, 2020, 14, .	1.1	16
16	Model Selection for G-Estimation of Dynamic Treatment Regimes. Biometrics, 2019, 75, 1205-1215.	1.4	6
17	Assessing the role of transmission chains in the spread of HIV-1 among men who have sex with men in Quebec, Canada. PLoS ONE, 2019, 14, e0213366.	2.5	7
18	A Hidden Markov Model for Identifying Differentially Methylated Sites in Bisulfite Sequencing Data. Biometrics, 2019, 75, 210-221.	1.4	9

#	Article	IF	CITATIONS
19	A cureâ€rate model for Qâ€learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients. Biometrical Journal, 2019, 61, 442-453.	1.0	5
20	Should a propensity score model be super? The utility of ensemble procedures for causal adjustment. Statistics in Medicine, 2019, 38, 1690-1702.	1.6	19
21	Modeling Chronic Obstructive Pulmonary Disease Progression Using Continuous-Time Hidden Markov Models. Studies in Health Technology and Informatics, 2019, 264, 920-924.	0.3	4
22	Variable Selection in Causal Inference using a Simultaneous Penalization Method. Journal of Causal Inference, 2018, 6, .	1.2	22
23	Estimating prevalence using indirect information and Bayesian evidence synthesis. Canadian Journal of Statistics, 2018, 46, 673-689.	0.9	1
24	A doubly robust weighting estimator of the average treatment effect on the treated. Stat, 2018, 7, e205.	0.4	10
25	DM-PhyClus: a Bayesian phylogenetic algorithm for infectious disease transmission cluster inference. BMC Bioinformatics, 2018, 19, 324.	2.6	6
26	Bayesian adaptive trials for rare cardiovascular conditions. Future Cardiology, 2018, 14, 143-150.	1.2	3
27	Reward ignorant modeling of dynamic treatment regimes. Biometrical Journal, 2018, 60, 991-1002.	1.0	6
28	Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec. Aids, 2017, 31, 707-717.	2.2	31
29	Treatment Prediction, Balance, and Propensity Score Adjustment. Epidemiology, 2017, 28, e51-e53.	2.7	10
30	Regularization and selection in Gaussian mixture of autoregressive models. Canadian Journal of Statistics, 2017, 45, 356-374.	0.9	8
31	Model validation and selection for personalized medicine using dynamic-weighted ordinary least squares. Statistical Methods in Medical Research, 2017, 26, 1641-1653.	1.5	7
32	An R Package for G-estimation of Structural Nested Mean Models. Epidemiology, 2017, 28, e18-e20.	2.7	8
33	Dynamic Treatment Regimen Estimation via Regression-Based Techniques: Introducing <i>R</i> Package DTRreg . Journal of Statistical Software, 2017, 80, .	3.7	19
34	Multivariate and Longitudinal Health System Indicators. Studies in Health Technology and Informatics, 2017, 235, 266-270.	0.3	1
35	Assessment of Overlap of Phylogenetic Transmission Clusters and Communities in Simple Sexual Contact Networks: Applications to HIV-1. PLoS ONE, 2016, 11, e0148459.	2.5	28
36	Optimal individualized dosing strategies: A pharmacologic approach to developing dynamic treatment regimens for continuousâ€valued treatments. Biometrical Journal, 2016, 58, 502-517.	1.0	9

#	Article	IF	CITATIONS
37	Treatment of Amblyopia Using Personalized Dosing Strategies: Statistical Modelling and Clinical Implementation. Strabismus, 2016, 24, 161-168.	0.7	4
38	A Bayesian view of doubly robust causal inference: Table 1 Biometrika, 2016, 103, 667-681.	2.4	31
39	Approximate Bayesian Inference for Doubly Robust Estimation. Bayesian Analysis, 2016, 11, .	3.0	22
40	SMART Thinking: a Review of Recent Developments in Sequential Multiple Assignment Randomized Trials. Current Epidemiology Reports, 2016, 3, 225-232.	2.4	10
41	Model Assessment in Dynamic Treatment Regimen Estimation via Double Robustness. Biometrics, 2016, 72, 855-864.	1.4	19
42	Influence Re-weighted G-Estimation. International Journal of Biostatistics, 2016, 12, 157-177.	0.7	0
43	Two-sample Bayesian Nonparametric Hypothesis Testing. Bayesian Analysis, 2015, 10, .	3.0	53
44	On Bayesian Estimation of Marginal Structural Models. Biometrics, 2015, 71, 279-288.	1.4	29
45	The Gap Procedure: for the identification of phylogenetic clusters in HIV-1 sequence data. BMC Bioinformatics, 2015, 16, 355.	2.6	17
46	Personalized versus standardized dosing strategies for the treatment of childhood amblyopia: study protocol for a randomized controlled trial. Trials, 2015, 16, 189.	1.6	10
47	Linear growth faltering in infants is associated with Acidaminococcus sp. and community-level changes in the gut microbiota. Microbiome, 2015, 3, 24.	11.1	120
48	Predictive Bayesian inference and dynamic treatment regimes. Biometrical Journal, 2015, 57, 941-958.	1.0	10
49	Rejoinder "On Bayesian Estimation of Marginal Structural Models― Biometrics, 2015, 71, 299-301.	1.4	4
50	Discussion of "Deductive Derivation and Turing-Computerization of Semiparametric Efficient Estimation―by Frangakis et al Biometrics, 2015, 71, 880-880.	1.4	0
51	Double Bias: Estimation of Causal Effects from Length-Biased Samples in the Presence of Confounding. International Journal of Biostatistics, 2015, 11, 69-89.	0.7	0
52	New quantitative approaches reveal the spatial preference of nuclear compartments in mammalian fibroblasts. Journal of the Royal Society Interface, 2015, 12, 20140894.	3.4	0
53	A marginal structural model for multiple-outcome survival data:assessing the impact of injection drug use on several causes of death in the Canadian Co-infection Cohort. Statistics in Medicine, 2014, 33, 1409-1425.	1.6	15
54	Propensity score estimation in the presence of lengthâ€biased sampling: a nonâ€parametric adjustment approach. Stat, 2014, 3, 83-94.	0.4	6

#	Article	IF	CITATIONS
55	Quantifying Causal Effects of Road Network Capacity Expansions on Traffic Volume and Density via a Mixed Model Propensity Score Estimator. Journal of the American Statistical Association, 2014, 109, 1440-1449.	3.1	21
56	hGH isoform differential immunoassays applied to blood samples from athletes: Decision limits for anti-doping testing. Growth Hormone and IGF Research, 2014, 24, 205-215.	1.1	12
57	Simulating sequential multiple assignment randomized trials to generate optimal personalized warfarin dosing strategies. Clinical Trials, 2014, 11, 435-444.	1.6	24
58	Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome, 2013, 1, 18.	11.1	107
59	The effect of amblyopia treatment on stereoacuity. Journal of AAPOS, 2013, 17, 166-173.	0.3	56
60	Quantifying the Effect of Area Deprivation on Child Pedestrian Casualties by Using Longitudinal Mixed Models to Adjust for Confounding, Interference and Spatial Dependence. Journal of the Royal Statistical Society Series A: Statistics in Society, 2013, 176, 931-950.	1.1	14
61	Compliance With Occlusion Therapy for Childhood Amblyopia. , 2013, 54, 6158.		96
62	Pricing American Options in an Infinite Activity Lévy Market: Monte Carlo and Deterministic Approaches Using a Diffusion Approximation. Springer Proceedings in Mathematics, 2012, , 291-321.	0.5	0
63	Estimation of dose–response functions for longitudinal data using the generalised propensity score. Statistical Methods in Medical Research, 2012, 21, 149-166.	1.5	16
64	A Bayesian Model of NMR Spectra for the Deconvolution and Quantification of Metabolites in Complex Biological Mixtures. Journal of the American Statistical Association, 2012, 107, 1259-1271.	3.1	41
65	Analysis of Spatial Point Patterns in Nuclear Biology. PLoS ONE, 2012, 7, e36841.	2.5	5
66	Complexity in Systems Level Biology and Genetics: Statistical Perspectives. , 2012, , 561-578.		0
67	Inference for Lévyâ€Ðriven Stochastic Volatility Models via Adaptive Sequential Monte Carlo. Scandinavian Journal of Statistics, 2011, 38, 1-22.	1.4	99
68	On inference from Markov chain macro-data using transforms. Journal of Statistical Planning and Inference, 2011, 141, 3201-3216.	0.6	3
69	Transmission Clustering Drives the Onward Spread of the HIV Epidemic Among Men Who Have Sex With Men in Quebec. Journal of Infectious Diseases, 2011, 204, 1115-1119.	4.0	105
70	Spatial Point Process Analysis of Promyelocytic Leukemia Nuclear Bodies. , 2011, , 59-85.		1
71	Methodology for Quantitative Analysis of 3-D Nuclear Architecture. , 2011, , 173-187.		2
72	Comparing Approaches to Causal Inference for Longitudinal Data: Inverse Probability Weighting versus Propensity Scores. International Journal of Biostatistics, 2010, 6, Article 14.	0.7	24

#	Article	IF	CITATIONS
73	Special Issue on Causal Inference. International Journal of Biostatistics, 2010, 6, Article 1.	0.7	1
74	HEDGING STRATEGIES AND MINIMAL VARIANCE PORTFOLIOS FOR EUROPEAN AND EXOTIC OPTIONS IN A LÉV MARKET. Mathematical Finance, 2010, 20, 617-646.	Y 1.8	5
75	Model Checking with Residuals for g-estimation of Optimal Dynamic Treatment Regimes. International Journal of Biostatistics, 2010, 6, Article 12.	0.7	18
76	The explicit chaotic representation of the powers of increments of Lévy processes. Stochastics, 2010, 82, 257-290.	1.1	3
77	Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. Journal of Clinical Investigation, 2010, 120, 1848-1861.	8.2	488
78	Using Bayesian inference to understand the allocation of resources between sexual and asexual reproduction. Journal of the Royal Statistical Society Series C: Applied Statistics, 2009, 58, 143-170.	1.0	8
79	Segmentation of Fluorescence Microscopy Images for Quantitative Analysis of Cell Nuclear Architecture. Biophysical Journal, 2009, 96, 3379-3389.	0.5	29
80	Interacting sequential Monte Carlo samplers for trans-dimensional simulation. Computational Statistics and Data Analysis, 2008, 52, 1765-1791.	1.2	33
81	Decomposing the impact of deprivation on child pedestrian casualties in England. Accident Analysis and Prevention, 2008, 40, 1351-1364.	5.7	24
82	Quantitative Analysis of Cell Nucleus Organisation. PLoS Computational Biology, 2007, 3, e138.	3.2	21
83	Simulation and inference for stochastic volatility models driven by Levy processes. Biometrika, 2007, 94, 627-646.	2.4	26
84	Population-Based Reversible Jump Markov Chain Monte Carlo. Biometrika, 2007, 94, 787-807.	2.4	73
85	Objectively monitored patching regimens for treatment of amblyopia: randomised trial. BMJ: British Medical Journal, 2007, 335, 707.	2.3	127
86	Modeling Dose-Response in Amblyopia: Toward a Child-Specific Treatment Plan. , 2007, 48, 2589.		78
87	Stochastic volatility modelling in continuous time with general marginal distributions: Inference, prediction and model selection. Journal of Statistical Planning and Inference, 2007, 137, 3068-3081.	0.6	30
88	Demystifying Optimal Dynamic Treatment Regimes. Biometrics, 2007, 63, 447-455.	1.4	162
89	On population-based simulation for static inference. Statistics and Computing, 2007, 17, 263-279.	1.5	147
90	Intermediate spatial frequency letter contrast sensitivity: its relation to visual resolution before and during amblyopia treatment. Ophthalmic and Physiological Optics, 2006, 26, 1-4.	2.0	13

#	Article	IF	CITATIONS
91	Bayesian analysis of quasi-life tables. Lifetime Data Analysis, 2006, 12, 117-141.	0.9	0
92	Bayesian Mixture Modelling in Geochronology via Markov Chain Monte Carlo. Mathematical Geosciences, 2006, 38, 269-300.	0.9	57
93	A Quantitative Study of Gene Regulation Involved in the Immune Response of Anopheline Mosquitoes. Journal of the American Statistical Association, 2006, 101, 18-29.	3.1	170
94	The Transcriptional Regulator CBP Has Defined Spatial Associations within Interphase Nuclei. PLoS Computational Biology, 2006, 2, e139.	3.2	24
95	Markov Chain Monte Carlo Methods and the Label Switching Problem in Bayesian Mixture Modeling. Statistical Science, 2005, 20, 50.	2.8	461
96	Treatment of Unilateral Amblyopia: Factors Influencing Visual Outcome. , 2005, 46, 3152.		140
97	Bayesian coclustering of Anopheles gene expression time series: Study of immune defense response to multiple experimental challenges. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16939-16944.	7.1	56
98	Triiodothyronine Stimulates Food Intake via the Hypothalamic Ventromedial Nucleus Independent of Changes in Energy Expenditure. Endocrinology, 2004, 145, 5252-5258.	2.8	138
99	Treatment Dose-Response in Amblyopia Therapy: The Monitored Occlusion Treatment of Amblyopia Study (MOTAS). , 2004, 45, 3048.		253
100	Large-sample properties of the periodogram estimator of seasonally persistent processes. Biometrika, 2004, 91, 613-628.	2.4	5
101	Bayesian analysis of discrete time warranty data. Journal of the Royal Statistical Society Series C: Applied Statistics, 2004, 53, 195-217.	1.0	19
102	Bayesian time series analysis of periodic behaviour and spectral structure. International Journal of Forecasting, 2004, 20, 713-730.	6.5	10
103	Quantification of automobile insurance liability: a Bayesian failure time approach. Insurance: Mathematics and Economics, 2004, 34, 1-21.	1.2	8
104	Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. European Heart Journal, 2004, 25, 431-436.	2.2	91
105	On the Analysis of Quasi-Life Tables. Lifetime Data Analysis, 2003, 9, 345-355.	0.9	6
106	Dose-Response Functions for Occlusion Treatment of Amblyopia. Clinical Science, 2003, 104, 62P-62P.	0.0	0
107	Design of the Monitored Occlusion Treatment of Amblyopia Study (MOTAS). British Journal of Ophthalmology, 2002, 86, 915-919.	3.9	63
108	Miscellanea. A multivariate family of distributions on (0, Â)p. Biometrika, 1999, 86, 703-709.	2.4	14

#	Article	IF	CITATIONS
109	Estimating linkage heterogeneity. Annals of Human Genetics, 1996, 60, 161-169.	0.8	3
110	Bayesian Analysis of Errors-in-Variables Regression Models. Biometrics, 1995, 51, 1085.	1.4	97
111	Estimating multipoint recombination fractions. Annals of Human Genetics, 1995, 59, 307-321.	0.8	3
112	Bayesian inference in multipoint gene mapping. Annals of Human Genetics, 1993, 57, 65-82.	0.8	32
113	Sampling-resampling techniques for the computation of posterior densities in normal means problems. Test, 1992, 1, 1-18.	1.1	13
114	Hedging Strategies and Minimal Variance Portfolios for European and Exotic Options in a Levy Market. SSRN Electronic Journal, 0, , .	0.4	1
115	Bayesian clustering for continuousâ€time hidden Markov models. Canadian Journal of Statistics, 0, , .	0.9	Ο